Zacks Investment Research upgraded shares of Auspex Pharmaceuticals Inc. (ASPX) from N/A to OUTPERFORM on November 12, 2014, with a target price of $36.00.
We are initiating coverage of Auspex Pharmaceuticals (ASPX) with a Buy rating and a $36 price target. Auspex is developing SD-809, a deuterium substituted version of the established neurological drug tetrabenazine as a treatment for Huntington's Disease (HD) and other movement disorders. The company has received orphan drug designation for SD-809 for the treatment of HD. Data from the two Phase 3 trials of SD-809 in HD are expected in December 2014. In addition, the company has initiated two Phase 3 trials for SD-809 in the treatment of tardive dyskinesia with results due in mid-2015 and 2016. Lastly, the company is testing SD-809 as a treatment for Tourette syndrome with results from the ongoing Phase 1b trial expected in mid-2015.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Auspex Pharmaceuticals Inc. (ASPX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment